Bill > HB2429

This bill modifies provisions relating to investigational drugs. The key changes are: 1. It allows manufacturers to make investigational drugs, biological products, or devices available to eligible patients, even if the drug is a Schedule I controlled substance (like certain psychedelics), as long as it has successfully completed phase one of a clinical trial but is not yet approved by the FDA. 2. It prohibits state agencies or regulatory boards from taking action against a physician's license or a health care provider's Medicare certification solely based on their recommendation of an investigational drug to an eligible patient. 3. It provides liability protections for those who manufacture, import, distribute, prescribe, dispense, or administer an investigational drug or device to an eligible patient, except in cases of gross negligence or willful misconduct. 4. It also modifies the possession of controlled substances law to exclude certain psychedelics from being considered an offense if the possession is in accordance with the investigational drug provisions in the bill.

Health and Social Services

https://www.house.mo.gov/Bill.aspx?bill=HB2429&year=2022&code=R